About Actelion
Actelion is a company based in Allschwil (Switzerland) founded in 1997 was acquired by Johnson & Johnson in January 2017.. Actelion has raised $46 million across 2 funding rounds from investors including Johnson & Johnson, 3i Group and Atlas Venture. Actelion has completed 3 acquisitions, including Axovan, Ceptaris Therapeutics and CoTherix. Actelion operates in a competitive market with competitors including Aerovate Therapeutics, Centessa Pharmaceuticals, Vivus, Biosion and Tenax Therapeutics, among others.
- Headquarter Allschwil, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Actelion Pharmaceuticals India Private Limited
- Date of Incorporation 08 Feb, 2008
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$46 M (USD)
in 2 rounds
-
Latest Funding Round
$34 M (USD), Series B
Mar 01, 1999
-
Investors
Johnson & Johnson
& 5 more
-
Employee Count
Employee Count
-
Investments & Acquisitions
Axovan
& 2 more
-
Acquired by
Johnson & Johnson
(Jan 26, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Software Development Team
294 people
Leadership Team
141 people
Senior Team
50 people
Finance and Accounting
45 people
Data Analysis and Operations Team
41 people
Product Management Team
26 people
Legal and Compliance
26 people
Human Resources and Administration
26 people
Unlock access to complete
Funding Insights of Actelion
Actelion has successfully raised a total of $46M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $34 million completed in March 1999. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $34.0M
-
First Round
First Round
(01 May 1998)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 1999 | Amount | Series B - Actelion | Valuation |
investors |
|
| May, 1998 | Amount | Series A - Actelion | Valuation | 3i Group , TVM Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Actelion
Actelion has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Johnson & Johnson, 3i Group and Atlas Venture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital is invested in life science innovations for healthcare transformation.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on mid-market businesses
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Actelion
Actelion has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Axovan, Ceptaris Therapeutics and CoTherix. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Mechlorethamine gel for mycosis fungoides is developed by Ceptaris Therapeutics.
|
2002 | ||||
|
Drug development company specializing in G Protein-Coupled Receptors (GPCRs) targeting therapeutics
|
2000 | ||||
|
Inhaled therapeutics for cardiopulmonary diseases were developed and licensed.
|
2000 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Actelion
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Actelion Comparisons
Competitors of Actelion
Actelion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aerovate Therapeutics, Centessa Pharmaceuticals, Vivus, Biosion and Tenax Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutic solutions for pulmonary arterial hypertension are developed.
|
|
| domain | founded_year | HQ Location |
Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for obesity and sexual health
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics to address cardiovascular and pulmonary diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Actelion
Frequently Asked Questions about Actelion
When was Actelion founded?
Actelion was founded in 1997 and raised its 1st funding round 1 year after it was founded.
Where is Actelion located?
Actelion is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.
Is Actelion a funded company?
Actelion is a funded company, having raised a total of $46M across 2 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on May 01, 1998.
What does Actelion do?
Actelion specializes in small molecule therapeutics for orphan diseases. Actelion scientists were among the first to work in the field of endothelian receptor antagonists. Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. Actelion currently has 10 compounds in its pipeline including 3 in late-stage development and 4 medicines on the market for orphan diseases: Tracleer (bosentan), a dual endothelin receptor antagonist which was the first oral treatment approved for pulmonary arterial hypertension; Zavesca (miglustat), currently the only approved oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Ventavis (iloprost), indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms; Veletri (epoprostenol for injection), approved for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Who are the top competitors of Actelion?
Actelion's top competitors include Aerovate Therapeutics, Vivus and Centessa Pharmaceuticals.
How many acquisitions has Actelion made?
Actelion has made 3 acquisitions, including Axovan, Ceptaris Therapeutics, and CoTherix.
Who are Actelion's investors?
Actelion has 6 investors. Key investors include Johnson & Johnson, 3i Group, Atlas Venture, TVM Capital Life Science, and NeoMed.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.